LuciBriga (Brigatinib) 90mg/180mg*30's | Generic ALK Inhibitor Laos | GLT

REQUEST A QUOTE

For individuals and institutions — pricing, availability, and product documents (COA) provided within 24 hours.
Direct line: [email protected] · +86 15234153837

分享
Product description

Generic Information: LuciBriga (Laos)

LuciBriga is a Lao-manufactured generic of brigatinib, produced by Lucius Pharmaceuticals. It is available in 90 mg and 180 mg strengths, each in a 30-tablet pack, which mirrors the two dosing steps of the standard brigatinib schedule. As a generic second-generation ALK inhibitor, LuciBriga offers the same active ingredient as the originator at a lower, out-of-pocket-friendly price.

What Is LuciBriga Used For?

LuciBriga is used for the first-line and post-crizotinib treatment of anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer. The two strengths let a patient start at 90 mg once daily and then escalate to 180 mg once daily, all with the same brand. A genetic test confirming the ALK rearrangement is required before prescribing.

How Does LuciBriga (Brigatinib) Work?

The brigatinib in LuciBriga is a next-generation ALK tyrosine kinase inhibitor that also targets ROS1, IGF-1R, and FLT-3. It blocks ALK-driven growth signaling and crosses the blood-brain barrier, making it effective against brain metastases. Because the generic delivers the same pharmacology as the originator, it can serve as a cost-saving substitute for the branded drug.

Indications

LuciBriga is indicated for adults with ALK-positive, locally advanced or metastatic NSCLC, both as initial therapy and after progression on crizotinib. It is not suitable for ALK-negative tumors and is not indicated for small-cell lung cancer.

Dosage

The recommended regimen begins with 90 mg once daily for 7 days, increasing to 180 mg once daily if tolerated. Take the tablet with or without food, at the same time each day, and swallow it whole. If a dose is missed or vomiting occurs, do not take an extra tablet — continue with the next scheduled dose. A treatment gap of 14 days or more requires a fresh 7-day 90 mg lead-in.

Side Effects

Common side effects include diarrhea, rash, cough, hypertension, fatigue, nausea, muscle pain, and headache. Blood pressure should be monitored, and diarrhea is generally manageable with supportive care. Interstitial lung disease is rare but serious, and treatment must be stopped permanently if it is confirmed.

Storage

Keep LuciBriga below 30°C in a dry place, in the original packaging, and away from children. No cold storage is required.

Why Choose the GLT?

For patients paying out of pocket, a Lao generic such as LuciBriga provides a meaningful cost advantage over the originator brand. The originator's Western list price is very high, while Lao generic brigatinib is priced far more affordably, making long-term daily therapy more financially sustainable. GLT sources from verified manufacturers and helps with the documentation needed for import.

How to Order

To order LuciBriga through GLT, message us on WhatsApp at +86 15234153837 or email [email protected]. Let us know whether you need 90 mg or 180 mg, the number of boxes, and your destination, and we will confirm availability, sourcing, and shipping terms.

FAQ

Is LuciBriga the same as Alunbrig? LuciBriga is a generic of brigatinib, the same active ingredient as Alunbrig, but produced by Lucius Pharmaceuticals in Laos. The pharmacology is equivalent, while the price is lower.

What strengths does LuciBriga come in? LuciBriga is available in 90 mg and 180 mg tablets, each in a 30-tablet pack, covering the lead-in and maintenance steps of the dosing schedule.

Where can I buy generic brigatinib? Generic brigatinib can be sourced through international suppliers such as GLT. Always verify the supplier and request proper documentation before purchasing.

Related Oncology Products

欣可平 XinKePing(阿伐曲泊帕)20mg*10片 | 南京恒生制药 | GLT

欣可平——南京恒生制药(济民可信集团)马来酸阿伐曲泊帕片,原料药与制剂一体化生产,中国大陆

Barinib(巴瑞替尼)2mg | 仿制 JAK1/JAK2 抑制剂 | Drug International Limited | GLT

由 Drug International Limited(孟加拉国)生产的仿制巴瑞替尼(JAK1/JAK2 抑制剂)——用于类风湿关节炎、特应性皮炎和斑秃,是 Olumiant 的平价替代品。

Avabopa(阿伐曲泊帕)20mg*30片 | 老挝东盟制药 TLPH | GLT

Avabopa——老挝东盟制药(TLPH)阿伐曲泊帕 20mg,老挝注册号 07 L 0990/23

奥氟格列隆/奥格列龙(OriYo)0.8–17.2mg 片剂 | 孟加拉仿制药 口服 GLP-1 | GLT

孟加拉国民制药(National Drug Co.)仿制奥氟格列隆,6 剂量递增用于体重管理

Tirzema(替尔泊肽)2.5/5/7.5mg/0.5mL 单剂量注射笔 | Incepta(孟加拉国)| GLT

Tirzema——Incepta Pharmaceuticals 替尔泊肽单剂量注射笔,三种官方规格(2.5/5/7.5mg/0.5mL),用于 2 型糖尿病和体重管理。

Barinat(巴瑞替尼)4mg | 仿制 JAK1/JAK2 抑制剂 | Natco Pharma Limited | GLT

由 Natco Pharma Limited(印度)生产的仿制巴瑞替尼(JAK1/JAK2 抑制剂)——用于类风湿关节炎、特应性皮炎和斑秃,是 Olumiant 的平价替代品。

奥氟格列隆/奥格列龙(LuciOrfor)0.8–17.2mg 片剂 | 老挝仿制药 口服 GLP-1 | GLT

卢修斯制药(老挝)有限公司出品奥氟格列隆(奥格列龙)仿制药,6 档剂量递增方案,用于体重管理